Related Experiment Videos

Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target

Ginés Sanz1, Valentin Fuster

  • 1Department of Translational Research, CNIC, Madrid, Spain. gsanz@cnic.es

Nature Clinical Practice. Cardiovascular Medicine
|December 24, 2008
PubMed

Insights

Fixed-dose combination therapy, or polypills, offer a promising solution to improve cardiovascular disease prevention in low-income countries. This approach enhances treatment adherence and affordability, crucial for combating leading global causes of death.

Area of Science:

  • Cardiovascular Medicine
  • Public Health
  • Pharmacology

Background:

  • Ischemic heart disease and stroke are the leading global causes of mortality.
  • High-risk populations for cardiovascular events are concentrated in low- and middle-income countries.
  • Existing pharmacological treatments face challenges like poor adherence, limited availability, and high costs in developing nations.

Purpose of the Study:

  • To examine the potential of fixed-dose combination therapy (polypill) in improving cardiovascular disease prevention.
  • To assess how polypills can enhance treatment adherence and affordability in low-income settings.

Main Methods:

  • Review of evidence supporting pharmacological interventions for cardiovascular event prevention.
  • Analysis of challenges hindering the efficacy of current cardiovascular prevention strategies.
  • Exploration of fixed-dose combination therapy as a potential solution.

Main Results:

  • Fixed-dose combination therapy (polypill) demonstrates potential to overcome adherence barriers.
  • Polypills can significantly reduce treatment costs and improve affordability.
  • This approach addresses key limitations of current cardiovascular prevention in resource-limited settings.

Conclusions:

  • Fixed-dose combination therapy represents a viable strategy to enhance cardiovascular event prevention in low-income countries.
  • The polypill model can improve patient adherence and make essential treatments more accessible and affordable.
  • Wider adoption of polypills could substantially impact global cardiovascular mortality rates.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...